Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Veracyte Inc (NQ: VCYT ) 32.21 -1.27 (-3.79%) Streaming Delayed Price Updated: 11:39 AM EDT, Oct 9, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Veracyte Inc < Previous 1 2 3 4 5 6 7 8 9 10 Next > New Artificial Intelligence Tool Can Diagnose Colon Cancer May 03, 2023 A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and... Via PressReach Topics Artificial Intelligence Death Exposures Artificial Intelligence Death Product Safety Veracyte Announces Release of Inaugural ESG Report May 03, 2023 From Veracyte, Inc. Via Business Wire A Preview Of Veracyte's Earnings February 21, 2023 Via Benzinga Data Published in "The Red Journal” Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer May 02, 2023 From Veracyte, Inc. Via Business Wire Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference May 01, 2023 From Veracyte, Inc. Via Business Wire Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier April 29, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting April 27, 2023 From Veracyte, Inc. Via Business Wire New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification April 17, 2023 From Veracyte, Inc. Via Business Wire Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023 April 13, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting April 12, 2023 From Veracyte, Inc. Via Business Wire Biotech And Life Science Trades: Q1 2023 Performance By The Numbers April 01, 2023 Despite a strong month and a great finish to the quarter, many traders remain cautious about the market. It’s been a volatile time after the collapse of Silicon Valley Bank, but the first quarter of... Via Talk Markets Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners March 15, 2023 From Veracyte, Inc. Via Business Wire 7 Biotech Stocks That Could Be the Next Big Thing March 15, 2023 Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough. Via InvestorPlace Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank March 11, 2023 From Veracyte, Inc. Via Business Wire Double-Digit Sales Growth: Is This Stock a Convincing Buy for Growth Investors? March 10, 2023 This diagnostics test maker has held up well over the last year. Via The Motley Fool Veracyte to Participate in Upcoming Investor Conferences February 27, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results February 22, 2023 From Veracyte, Inc. Via Business Wire SMID Cap Life Science Update: Are You An Investor Or Trader? February 20, 2023 Despite choppy trading, there is an upward tilt to life science stocks since the 9/26/22 lows. Via Talk Markets Data Published in “The Red Journal” Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer February 15, 2023 From Veracyte, Inc. Via Business Wire Earnings Scheduled For February 22, 2023 February 22, 2023 Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022. Via Benzinga New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment February 13, 2023 From Veracyte, Inc. Via Business Wire Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023 February 06, 2023 From Veracyte, Inc. Via Business Wire When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader? February 05, 2023 A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? Via Talk Markets Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium February 01, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules February 01, 2023 From Veracyte, Inc. Via Business Wire Better Long-Term Buy in 2023: Exact Sciences or Veracyte? January 24, 2023 As cancer screenings are becoming covered more often, both companies stand to gain. Via The Motley Fool Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors January 23, 2023 From Exagen Inc. Via GlobeNewswire Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock January 18, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023 January 18, 2023 Via Benzinga This Small-Cap Stock Is a No-Brainer Buy January 18, 2023 This genomic test maker's stock was beaten down in 2022. But it could be heading for a rebound this year. Via The Motley Fool < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.